Histogenesis and possible mechanism of chondroid changes in mixed tumour of the skin: immunohistochemical evaluation of bone morphogenetic protein, glycosaminoglycans, keratin, vimentin and neuronal markers.
The distribution of immunoreactivity of bone morphogenetic protein (BMP), the glycosaminoglycans chondroitin 4-sulphate (C4SPG), chondroitin 6-sulphate (C6SPG), dermatan sulphate (DSPG) and keratan sulphate proteoglycans (KSPG), cytokeratin (K8.12), vimentin, glial fibrillary acidic protein (GFAP), actin, desmin, S-100 protein and neuron-specific enolase (NSE) in mixed tumour of the skin was investigated using immunohistochemical methods using monoclonal (MoAb) and polyclonal antibodies (PoAb). A strong BMP immunoreactivity was found characteristically in outer tumour cells of tubuloductal structures and modified myoepithelial cells. Modified myoepithelial cells and chondroidally changed cells showed positive immunoreactivity for C4SPG, C6SPG and DSPG; and KSPG was more pronounced in the modified myoepithelial cells. Vimentin, S-100 protein, GFAP and NSE, but not actin and desmin, were distribute in the outer tumour cells and modified myoepithelial cells in chondroidally changed tissue. Two factors show that chondrogenesis in mixed tumour of the skin is associated with the modified myoepithelial cells through the activity of BMP and biosynthesis of glycosaminoglycans as matrix substance. First, outer or basal tumour cells in mixed tumour of the skin is characterized by the presence of positive immunoreactivity for BMP, KSPG, vimentin, cytokeratin K8.12, S-100 protein, GFAP and NSE, and second, there is a matrix of chondroidally changed tissue containing the reaction products of C4SPG, C6SPG, DSPF and KSPG.
Mori
M
M
Department of Oral and Maxillofacial Surgery, Asahi University School of Dentistry, Gifu, Japan.
Shrestha
P
P
Sakamoto
F
F
Yang
L J
LJ
Qin
C
C
Tsujimura
T
T
D000199:Actins / Q000378:metabolism; D006607:Adenoma, Sweat Gland / Q000378:metabolism*; D019485:Bone Morphogenetic Proteins; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism; D002809:Chondroitin Sulfates / Q000378:metabolism; D003871:Dermatan Sulfate / Q000378:metabolism; D003893:Desmin / Q000378:metabolism; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006025:Glycosaminoglycans / Q000378:metabolism*; D006801:Humans; D007632:Keratan Sulfate / Q000378:metabolism; D007633:Keratins / Q000378:metabolism*; D000071234:Lumican; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D011506:Proteins / Q000378:metabolism*; D009418:S100 Proteins / Q000378:metabolism; D013544:Sweat Gland Neoplasms / Q000378:metabolism*; D014746:Vimentin / Q000378:metabolism*
D000199:Actins; D019485:Bone Morphogenetic Proteins; D011508:Chondroitin Sulfate Proteoglycans; D003893:Desmin; D005904:Glial Fibrillary Acidic Protein; D006025:Glycosaminoglycans; C000604306:LUM protein, human; D000071234:Lumican; D011506:Proteins; D009418:S100 Proteins; D014746:Vimentin; D003871:Dermatan Sulfate; D007633:Keratins; D002809:Chondroitin Sulfates; D007632:Keratan Sulfate; D010751:Phosphopyruvate Hydratase